Brooklyn Investment Group Makes New $40,000 Investment in Poseida Therapeutics, Inc. (NASDAQ:PSTX)

Brooklyn Investment Group acquired a new stake in shares of Poseida Therapeutics, Inc. (NASDAQ:PSTX) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 4,149 shares of the company’s stock, valued at approximately $40,000.

A number of other large investors have also modified their holdings of the company. The Manufacturers Life Insurance Company increased its holdings in Poseida Therapeutics by 14.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 28,520 shares of the company’s stock valued at $83,000 after buying an additional 3,552 shares during the period. Rhumbline Advisers increased its stake in Poseida Therapeutics by 4.2% in the second quarter. Rhumbline Advisers now owns 97,012 shares of the company’s stock valued at $283,000 after acquiring an additional 3,875 shares during the period. American Century Companies Inc. lifted its stake in Poseida Therapeutics by 5.9% during the second quarter. American Century Companies Inc. now owns 90,487 shares of the company’s stock worth $264,000 after purchasing an additional 5,023 shares during the period. Dimensional Fund Advisors LP boosted its holdings in Poseida Therapeutics by 1.6% during the second quarter. Dimensional Fund Advisors LP now owns 599,812 shares of the company’s stock valued at $1,749,000 after purchasing an additional 9,672 shares in the last quarter. Finally, Marshall Wace LLP bought a new stake in shares of Poseida Therapeutics in the 2nd quarter valued at approximately $31,000. 46.87% of the stock is currently owned by institutional investors and hedge funds.

Poseida Therapeutics Price Performance

Shares of NASDAQ PSTX opened at $9.50 on Monday. Poseida Therapeutics, Inc. has a 12-month low of $1.87 and a 12-month high of $9.67. The firm’s 50-day simple moving average is $8.04 and its 200 day simple moving average is $4.71. The company has a quick ratio of 3.20, a current ratio of 3.20 and a debt-to-equity ratio of 0.68. The company has a market cap of $928.85 million, a price-to-earnings ratio of -15.08 and a beta of 1.63.

Insider Transactions at Poseida Therapeutics

In other Poseida Therapeutics news, Chairman Mark J. Gergen sold 30,000 shares of Poseida Therapeutics stock in a transaction dated Tuesday, December 10th. The shares were sold at an average price of $9.46, for a total value of $283,800.00. Following the completion of the sale, the chairman now owns 651,291 shares in the company, valued at $6,161,212.86. The trade was a 4.40 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 2.90% of the company’s stock.

Analyst Ratings Changes

Several analysts recently commented on the company. HC Wainwright reaffirmed a “neutral” rating and issued a $9.00 price target (down previously from $20.00) on shares of Poseida Therapeutics in a research note on Tuesday, November 26th. BTIG Research reaffirmed a “neutral” rating on shares of Poseida Therapeutics in a report on Tuesday, November 26th. Piper Sandler downgraded shares of Poseida Therapeutics from an “overweight” rating to a “neutral” rating and set a $10.00 price target for the company. in a report on Monday, December 2nd. Cantor Fitzgerald cut shares of Poseida Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, November 26th. Finally, William Blair reiterated a “market perform” rating on shares of Poseida Therapeutics in a research note on Tuesday, November 26th. Five equities research analysts have rated the stock with a hold rating, According to data from MarketBeat, Poseida Therapeutics presently has a consensus rating of “Hold” and an average target price of $9.50.

Poseida Therapeutics Company Profile

Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications.